Furosemide: Nursing Drug Guide, Electrolyte Depletion & NCLEX Review
High-ceiling loop diuretic for edema and hypertension: the bedside priority is electrolyte depletion—hypokalemia, hypomagnesemia, hyponatremia, and hypochloremic alkalosis—plus dehydration and hypotension when diuresis outpaces intake. IV furosemide given too rapidly with aminoglycosides raises ototoxicity risk; trend BMP, weight, I&O, and hold for oliguria or rising creatinine.
Labeling warns that excessive furosemide can cause profound diuresis with water and electrolyte depletion. Hypokalemia may develop with brisk diuresis, restricted salt intake, cirrhosis, corticosteroids, or laxatives—and digitalis therapy may exaggerate myocardial effects of hypokalemia. Excessive diuresis may cause dehydration with circulatory collapse. Rapid IV injection increases ototoxicity risk, especially with aminoglycosides or severe renal impairment. Give only with careful medical supervision and individualized dosing.
📋 Contents
⚡ Quick facts
💡 Key takeaway
Before every dose, review the latest basic metabolic panel, daily weight, and intake and output. Hold furosemide when potassium is low, urine output is inadequate, or creatinine rises sharply—then notify the prescriber or pharmacist. Pair diuresis with edema assessment and teach patients to report cramps and dizziness on standing.
Most common brand names
Lasix is the most recognized U.S. brand for furosemide tablets and injection. Generic furosemide is widely available in 20 mg, 40 mg, and 80 mg oral strengths and as 10 mg/mL injection for IV or IM use. Verify tablet strength on every pass—20 mg, 40 mg, and 80 mg are not interchangeable without a prescriber order.
Many heart-failure regimens combine furosemide with spironolactone or other potassium-sparing agents; confirm whether both are intentional before questioning duplicate diuretic therapy.
Why we give it — Indications
U.S. prescribing information lists furosemide for edema associated with congestive heart failure, cirrhosis of the liver, and renal disease including nephrotic syndrome—when an agent with greater diuretic potential is desired. It may also be used in adults for hypertension alone or with other antihypertensive agents (hypertensive patients inadequately controlled on thiazides alone will probably not be adequately controlled with furosemide alone per labeling).
| Use | Detail |
|---|---|
| Edema / fluid overload | Reduce excess fluid in heart failure, hepatic disease, or renal disease; monitor for over-diuresis |
| Acute pulmonary edema (IV) | Initial 40 mg IV slow push; may increase to 80 mg if no response within 1 hour per injection labeling |
| Hypertension (oral) | Usual initial 80 mg/day divided (e.g., 40 mg twice daily); add other agents if response inadequate |
On a small screen, swipe or scroll sideways to see the full table.
How it works
Furosemide inhibits sodium and chloride reabsorption in the proximal and distal tubules and in the loop of Henle, producing rapid, high-ceiling diuresis. Oral onset is within about 1 hour with peak effect in the first or second hour and duration of 6 to 8 hours per tablet labeling. Expected losses include potassium, magnesium, and calcium—nurses should anticipate hypokalemia, hypomagnesemia, hypocalcemia (rarely tetany), and hypochloremic metabolic alkalosis.
Dosing overview
Individualize dose to the minimal amount needed for therapeutic response. Labeling emphasizes careful medical supervision because excessive amounts can cause profound diuresis with water and electrolyte depletion.
Renal impairment: May be used when diuresis is needed, but discontinue if increasing azotemia and oliguria occur during treatment of severe progressive renal disease per labeling.
Hepatic impairment: In cirrhosis with ascites, initiate in hospital; sudden fluid/electrolyte shifts may precipitate hepatic coma—strict observation required.
Missed dose: Not specified in the reviewed prescribing information; follow prescriber or pharmacy guidance.
Onset, peak, and duration
- Oral: Diuresis begins within 1 hour; peak in first or second hour; duration 6–8 hours
- IV/IM: Prompt diuresis; give slowly over 1–2 minutes for bolus doses
- Half-life: Approximately 2 hours (terminal half-life per labeling)
- High-dose IV infusion: When used, rate not exceeding 4 mg/min for adults has been used per injection labeling
Before you give it — Safety check
Pretreatment checks
- Latest BMP: potassium, sodium, chloride, bicarbonate/CO2, creatinine, BUN, glucose
- Baseline weight, blood pressure, and orthostatic vitals when diuresis is aggressive
- Confirm patient is not in anuria; review allergies (sulfonamide cross-reactivity possible per labeling)
- Review interacting drugs: digoxin, ACE inhibitors/ARBs, NSAIDs, aminoglycosides, lithium
Contraindications
- Anuria
- History of hypersensitivity to furosemide
Important interactions
| Drug / class | Effect | Nursing action |
|---|---|---|
| Digoxin | Hypokalemia increases digoxin toxicity risk; labeling warns digitalis may exaggerate myocardial effects of hypokalemia | Trend potassium; hold furosemide for symptomatic hypokalemia; obtain rhythm assessment |
| ACE inhibitors / ARBs | May cause severe hypotension and deterioration in renal function including renal failure | Monitor BP and creatinine after initiation or dose changes; notify prescriber for symptomatic hypotension |
| NSAIDs (e.g., ibuprofen, indomethacin) | May reduce natriuretic/antihypertensive effect; case reports of increased BUN, creatinine, potassium, and weight gain | Assess edema response; teach patients to avoid hidden OTC NSAIDs unless prescriber approves |
| Aminoglycosides | Increased ototoxic potential, especially with impaired renal function; avoid except in life-threatening situations | Never rush IV push; monitor for tinnitus/hearing loss; coordinate timing with pharmacy |
On a small screen, swipe or scroll sideways to see the full table.
Administration
Oral: Tablets 20, 40, or 80 mg; may give on 2–4 consecutive days each week for safer long-term edema mobilization per labeling.
- IV/IM bolus: Inject slowly over 1 to 2 minutes per injection labeling
- Acute pulmonary edema: 40 mg IV slow push; may increase to 80 mg if no satisfactory response within 1 hour
- High-dose infusion: If ordered, administer controlled infusion not exceeding 4 mg/min; ensure compatible alkaline pH—do not mix with acidic IV drugs in same line
- Pair each dose with accurate urinary output measurement and orthostatic blood pressure checks when diuresis is brisk
Ototoxicity (tinnitus, hearing impairment, deafness) has been reported with rapid injection, higher-than-recommended doses, severe renal impairment, hypoproteinemia, or concurrent ototoxic drugs. Follow slow administration rates and use high-alert medication administration double-check practices for IV doses.
Expected therapeutic response
- Increased urine output within expected onset window for route given
- Decrease in edema, weight, or pulmonary congestion symptoms when treating fluid overload in heart failure
- Blood pressure reduction when used for hypertension (monitor for excessive drop when combined with other antihypertensives)
Red flags — Stop and act
Electrolyte loss and volume depletion can progress quickly—especially with repeated IV doses or combination diuretic therapy.
- Potassium below prescriber or protocol hold limit, new PVCs or ventricular ectopy, or digoxin on the MAR with falling K+
- Oliguria, acute weight loss, orthostatic hypotension, or confusion suggesting hypovolemia
- Marked rise in BUN/creatinine during diuresis in progressive renal disease—labeling indicates discontinuation
- New tinnitus, hearing loss, or vertigo—especially after IV doses with aminoglycosides
- Muscle cramps, weakness, tetany, or palpitations with electrolyte depletion on BMP
- Severe anaphylactic or anaphylactoid reaction, systemic vasculitis, or interstitial nephritis (reported per labeling)
Adverse effects
| Adverse effect | Notes (labeling) | Nursing response |
|---|---|---|
| Electrolyte imbalance | Hypokalemia, hyponatremia, hypochloremic alkalosis, hypomagnesemia, hypocalcemia | Trend BMP; hold dose and notify team for symptomatic or protocol-level abnormalities |
| Volume depletion | Dehydration, hypotension, orthostatic hypotension (aggravated by alcohol, barbiturates, narcotics) | Orthostatic vitals; fall precautions; assess I&O and weight |
| Ototoxicity | Tinnitus, hearing loss (reversible or irreversible), vertigo, paresthesias | Hold and notify prescriber; document IV rate and concurrent ototoxic drugs |
| GI effects | Nausea, vomiting, diarrhea, constipation, pancreatitis (reported) | Supportive care; differentiate from electrolyte-related GI symptoms |
| Hepatic encephalopathy | Reported in patients with hepatocellular insufficiency | Monitor mental status in cirrhosis; avoid rapid electrolyte shifts |
| Hyperglycemia / glycosuria | Altered glucose tolerance; rarely precipitation of diabetes mellitus | Monitor glucose in diabetic patients per labeling |
| Hypersensitivity / dermatologic | Rash, urticaria, photosensitivity; SJS/TEN reported | Discontinue at first sign of serious skin reaction; escalate urgently |
On a small screen, swipe or scroll sideways to see the full table.
Whenever adverse reactions are moderate or severe, furosemide dosage should be reduced or therapy withdrawn per labeling.
Overdose, toxicity, and antidote
Principal signs of overdose are extensions of diuretic action: dehydration, blood volume reduction, hypotension, electrolyte imbalance, hypokalemia, and hypochloremic alkalosis per labeling.
Antidote
Not specified in the reviewed prescribing information — there is no listed specific reversing agent. Treatment is supportive.
Management per labeling
- Replace excessive fluid and electrolyte losses with frequent monitoring of serum electrolytes, carbon dioxide level, and blood pressure
- Ensure adequate urinary drainage in bladder outlet obstruction (e.g., prostatic hypertrophy)
- Coordinate potassium and magnesium replacement per prescriber orders—often potassium chloride when safe
- Hemodialysis does not accelerate furosemide elimination
- Contact local poison control or medical toxicology services per facility protocol for significant overdose or instability
Look-alike / sound-alike and error prevention
- Furosemide vs torsemide vs bumetanide — all loop diuretics with different potency; never convert doses without pharmacist verification
- Lasix brand name — verbal orders may be misheard; confirm generic name and strength in writing
- 20 mg vs 40 mg vs 80 mg tablets — triple-check strength; use leading zeros only per institutional policy
- IV mg vs mL — 10 mg/mL concentration: 40 mg = 4 mL; independent double-check before push
- Duplicate loop diuretics — home furosemide plus inpatient IV ordering errors; perform medication reconciliation at every transition
Practical bedside notes
| Topic | Bedside guidance |
|---|---|
| Best timing | Many regimens give morning doses to avoid nocturia; follow MAR exactly |
| Daily weights | Same scale, same time, similar clothing—critical for heart failure diuresis |
| IV compatibility | Furosemide injection is alkaline (pH ~9); precipitation risk below pH 7—do not co-infuse with acidic drugs |
| Sucralfate separation | Separate sucralfate and furosemide by at least 2 hours per labeling |
| Photosensitivity | Labeling notes increased sun sensitivity—teach sun protection |
| Ask pharmacy when | Unclear dose conversion, IV compatibility questions, oliguria with rising creatinine, or suspected overdose |
On a small screen, swipe or scroll sideways to see the full table.
High-risk populations
| Population | Considerations |
|---|---|
| Older adults | Greater risk of excessive diuresis, dehydration, circulatory collapse, and thromboembolism; start at low end of dosing range and monitor renal function |
| Hepatic cirrhosis / ascites | Initiate in hospital; sudden fluid/electrolyte shifts may precipitate hepatic coma; supplement potassium and consider aldosterone antagonist per labeling |
| Progressive renal disease | Discontinue if increasing azotemia and oliguria occur during treatment |
| Diabetes mellitus | May increase blood glucose; monitor glucose and urine glucose tests |
| Pregnancy | Pregnancy Category C; no adequate well-controlled studies—use only if potential benefit justifies potential risk to fetus; maternal deaths and abortions reported in animal studies |
| Lactation | Appears in breast milk; caution advised; labeling notes furosemide may inhibit lactation |
| Premature infants / children <4 years | Risk of nephrocalcinosis/nephrolithiasis with chronic use—monitor renal function; renal ultrasonography should be considered per labeling |
On a small screen, swipe or scroll sideways to see the full table.
Monitoring and documentation
Monitor
- Serum electrolytes (especially potassium), CO2, creatinine, and BUN—frequently during first months and periodically thereafter per labeling
- Weight, I&O, blood pressure, and orthostatic vitals during active diuresis
- Telemetry or rhythm assessment when digoxin is co-prescribed and potassium is trending down
- Glucose in diabetic patients; magnesium and calcium periodically per labeling
- Signs of ototoxicity after IV doses, especially with aminoglycosides
Document
- Dose, route, time, indication, urine output response, and weight change
- Latest BMP values and any hold parameters triggered
- IV push rate confirmation and independent double-check for parenteral doses
- Patient teaching on cramps, dizziness, daily weights, and when to report symptoms
Patient teaching
- Report muscle cramps, weakness, dizziness on standing, palpitations, or decreased urination promptly
- Weigh yourself daily at the same time with similar clothing if instructed for heart failure management
- Do not take OTC NSAIDs or appetite suppressants without asking your prescriber—they can reduce diuretic effect or harm kidneys
- Take potassium supplements or eat high-potassium foods only as directed; do not self-treat low potassium
- Protect skin from sun; furosemide may increase photosensitivity
- Rise slowly from sitting or lying down to reduce orthostatic dizziness
The Hold Rule
Do not give and contact the prescriber/pharmacist when:
- Known furosemide allergy or active hypersensitivity reaction
- Anuria or oliguria without prescriber-directed plan
- Potassium, magnesium, or sodium below institutional hold parameters or symptomatic electrolyte depletion
- Symptomatic hypotension, orthostatic presyncope, or acute mental status change suggesting hypovolemia
- Marked creatinine/BUN rise during diuresis in progressive renal disease—discontinue per labeling until prescriber reviews
- New tinnitus or hearing change after IV dose, especially with concurrent aminoglycoside
Hold parameters may vary by institutional protocol. Follow prescriber orders, pharmacy guidance, and facility policy.
Clinical practice integration and workflow
Furosemide is one of the most frequently administered inpatient drugs—and one of the most common sources of preventable electrolyte injury when nurses treat it as routine without trending labs and I&O.
1. Check-before-you-give protocol
- Right patient, drug, dose, route, time—and right BMP within acceptable timeframe
- Compare today’s weight and net I&O to prescriber diuresis goals
- For IV doses: independent double-check of mg, mL, and slow-push plan (1–2 minutes)
- Scan MAR for digoxin, ACE inhibitor, NSAID, and aminoglycoside overlap
2. High-alert and safety badge
Not on all institutional high-alert lists, but potent loop-diuretic electrolyte risk requires BMP, I&O, and hold discipline comparable to high-alert drugsLabeling boxed warning emphasizes that excessive doses cause profound diuresis with water and electrolyte depletion requiring careful medical supervision.
3. Clinical workflow: hold and question rules
- If potassium is falling across shifts, hold the next dose and page the team before giving another loop diuretic
- If urine output drops while diuresis continues, clarify whether therapy is helping or harming renal perfusion
- Never accelerate IV push rate for convenience—ototoxicity reports link rapid injection to hearing injury
4. Critical teach-back questions
- “What symptoms should you report right away while taking this water pill?” (Patient should name cramps, palpitations, dizziness, decreased urination, or ringing in the ears.)
- “How will you track whether the diuretic is working safely at home?” (Patient should describe daily weights, fluid limits if ordered, and calling the team for rapid weight gain or loss.)
5. Care coordination
Pharmacist: Dose conversion between loop diuretics, interaction review with ACE inhibitors and NSAIDs, IV compatibility, and electrolyte replacement protocols
Prescriber: Notify for refractory edema, oliguria with rising creatinine, symptomatic hypokalemia, ototoxicity symptoms, or need to adjust diuretic regimen in cirrhosis or renal disease
🧠 Quick mental checklist
- What is the latest potassium—and is digoxin on the MAR?
- Does net I&O and weight match the prescriber’s diuresis goal?
- For IV: is this dose given slowly over 1–2 minutes?
- Any oliguria, rising creatinine, or orthostatic symptoms?
- Did I teach the patient what cramps, dizziness, and tinnitus mean?
Furosemide NCLEX practice questions
Practice NCLEX-style clinical judgment practice for furosemide using a tabbed heart-failure case (MAR, labs, I&O, nursing notes), then priority action, cue recognition SATA, electrolyte trend SATA, matrix urgency sorting, IV administration judgment, and overdose cloze—with explicit evaluate outcomes items after replacement therapy.
Select a tab to view MAR, labs, I&O, and nursing note details for this case.
- Furosemide 40 mg IV q12h scheduled — last dose 0600
- Digoxin 0.125 mg PO daily — given 0700
- Lisinopril 10 mg PO daily — given 0700
- Gentamicin 120 mg IV q24h — due 1400 per pharmacy stewardship note
- Home oral furosemide 40 mg BID held on admission pending IV regimen
- Admission K+ 4.1 mEq/L; yesterday 3.5; today 3.0 mEq/L (BMP 0800)
- Magnesium 1.7 mg/dL (low-normal)
- Creatinine 1.0 → 1.28 mg/dL over 48 h; BUN 22 → 34 mg/dL
- Urine output 3.8 L (Foley); intake 1.6 L — net negative ~2.2 L
- Weight 84.2 kg yesterday → 82.9 kg today
- Orthostatics: lying BP 118/72; standing BP 96/58 with HR +22 and reported lightheadedness
- 72-year-old with HFrEF admitted for volume overload; lungs clearer after overnight diuresis
- 0900: reports leg cramps and mild dizziness when transferring to chair
- Telemetry: frequent PVCs since 0830 correlating with falling potassium trend
- 1200: 40 mg IV furosemide due; nurse reviewing tabs before administration
Answer key & rationale
Frequently asked questions
What should I check before giving furosemide?
Review the latest basic metabolic panel (especially potassium, sodium, magnesium, creatinine, and BUN), compare weight and intake/output to diuretic goals, assess blood pressure and orthostatic symptoms, confirm the patient is not in anuria, and verify allergies and interacting drugs such as digoxin, ACE inhibitors, NSAIDs, and aminoglycosides. Match the ordered dose and route to the MAR and use slow IV administration per labeling when giving parenteral furosemide.
When should nurses hold furosemide?
Hold and contact the prescriber or pharmacist when potassium or magnesium is below protocol limits, the patient has symptomatic hypotension or orthostasis, urine output is inadequate (oliguria or anuria), creatinine or BUN rises sharply during diuresis, the patient reports new hearing loss or tinnitus (especially after IV doses with aminoglycosides), or there is known hypersensitivity. Do not give additional loop diuretic doses while these issues are unresolved unless the prescriber clarifies the plan.
Why is hypokalemia dangerous with furosemide and digoxin?
Furosemide causes potassium loss through loop diuresis. Labeling states that digitalis therapy may exaggerate the metabolic effects of hypokalemia, especially myocardial effects, increasing dysrhythmia risk even when digoxin levels appear therapeutic. Nurses should trend potassium with BMP monitoring, watch telemetry when ordered, and hold furosemide for symptomatic or protocol-level hypokalemia while notifying the team.
How fast can IV furosemide be given?
For routine IV or IM doses, labeling directs slow administration over 1 to 2 minutes. For high-dose parenteral therapy given by infusion, an adult rate not exceeding 4 mg furosemide per minute has been used. Rapid injection, higher-than-recommended doses, severe renal impairment, and concurrent ototoxic drugs increase the risk of hearing impairment per warnings.
Is there an antidote for furosemide overdose?
No specific antidote is listed in the reviewed prescribing information. Overdose signs reflect exaggerated diuretic action: dehydration, hypotension, and electrolyte imbalance including hypokalemia and hypochloremic alkalosis. Treatment is supportive—replace fluids and electrolytes with close monitoring of blood pressure, serum electrolytes, and urine output. Contact local poison control or medical toxicology services per facility protocol for significant overdose.
References
- U.S. National Library of Medicine. FUROSEMIDE tablet — SPL product labeling. DailyMed.https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=1d44526e-563e-4cd2-9625-983d8c31a434
- U.S. National Library of Medicine. FUROSEMIDE injection — SPL product labeling. DailyMed.https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c90bcb14-eb8d-4753-b339-3469c664ecd2
- Joint Formulary Committee. Furosemide monograph. BNF (NICE).https://bnf.nice.org.uk/drugs/furosemide/
Review and transparency
This medication guide is written and reviewed using NurseOnShift editorial and clinical review standards.
Educational use only. This content does not replace clinical judgment, prescriber orders, pharmacist guidance, product labeling, or institutional protocols.